Hey tx. I took a very quick look on pubmed. I'll give you my thoughts here as I don't subscribe to IH because I'm cheap. I don't know if the mods will delete this for being off topic, they seem to have a pretty low tolerance for such things.
Pros
- other drugs in same class already approved for vet uses
- new class of antibiotic, not a "me too" type drug
- low rate of bacterial resistance development - this is pretty
encouraging actually.
- shows activity against bacteria resistant to other classes of
antibiotics (this isn't unheard of in new classes of antibiotics)
- it is probably bactericidal (actually kills bacteria), not
bacteriostatic (keeps them from multiplying)
Cons - already in PIII, opportunity for early entry gone
- small company, will need to partner to distribute.
Don't know yet -
- Spectrum of activity - this is key. Ideally you want something
very broad spectrum that will be used lots, before culture
results are available and treatment is changed to something more
specific and more affordable.
- Side effects - like I said, I haven't looked too deeply into
this, I'm sure this information is out there.
- Cost of drug - All things being equal hospitals will use the
less expensive alternative.
- Failure rate - it can kill the bugs all day long in the test
tube, but how it does in a human can differ (you may hear this
referred to as in vivo vs in vitro activity)
News 
Market Data 
Discover 
